Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

TSX:EDT - Post by User

Spectral Medical Inc > The breadcrumbs I see in the IR

<< Previous

Bullboard Posts

Next >>

Comment by BayStreetWildon Oct 07, 2022 1:46pm

137 Views

Post# 35012765

RE:RE:RE:The breadcrumbs I see in the IR

HIGHLY UNLIKELY

PezDalatoYou wrote: What's the likelihood that a Dialco sale is already being finalized and they are now tying up loose ends?

Consider:
1. The ongoing DIMI useability trial delays on what should be the easiest to execute trial ever in the history of the FDA. In the May 13, 2022 PR it is stated that "The Dialco team...expects first patient enrollment in Q3 2022". This didn't happen or it hasn't been disclosed. Was the goal all along to tee up the outstanding trials to certain milestones as a prerequisite/condition of the sale?

2. Current round of financing excludes Dialco. A trial that is supposed to be enrolling patients right now needs funding right now. I'm getting the sense that there was no intention at all of performing the DIMI trial by this team.

3. Weirdness with Dialco/Infomed. Now they are working on: "Dialco has extended its DIMI license agreement with Infomed SA until November 30, 2022 as the parties evaluate strategic options for advancing DIMI". I thought that the Dialco/Infomed agreement was solid for the next decade. For what purpose are they tinkering with their agreement for the next two months?

4. The hiring of Sam Amory. He can pass along to the new owners while he finishes up his residency program at Dialco.

I hate trying to read between the lines!